Bone-Targeting Anthraquinone-Diclofenac Prodrugs with Hydrolytic and Bone Affinity Characteristics
Two hydrolytically activated anthraquinone-diclofenac prodrugs have been designed and synthesized. Both prodrugs show significant binding capability to hydroxyapative (HAP), the major component of bone, and hydrolytically activity in simulation physiological conditions in vitro.
Keywords: Bone-targeting, Anthraquinone, Prodrug, Hydrolytic, Bone affinity, Anti-inflammatory
Rights & PermissionsPrintExport